Русский
The clinical course of HIV/COVID-19 co-infection and approaches to its therapy
DOI: https://dx.doi.org/10.18565/epidem.2021.11.4.20-4
Kravchenko A.V., Kuimova U.A., Kanestri V.G., Goliusova M.D., Kulabukhova E.I.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Peoples’ Friendship University of Russia, Moscow, Russia
Patients. Eighty-five HIV-infected patients with coronavirus infection were examined. Their median age was 39 years. Seventy-six patients received ART. All had HIV RNA < 50 copies/ml; the median number of CD4+ lymphocytes was 602.5 cells/µl. Nine patients did not receive ART; the median number of CD4+ lymphocytes was 342 cells/µl; the median HIV RNA was 69 915.5 copies/µl. Concomitant diseases were present in 22.4% of the patients.
Results. The diagnosis of the disease was confirmed by the detection of SARS-CoV-2 RNA in the nasopharyngeal swabs (PCR) of 45 patients and by the presence of anti-SARS-CoV-2 IgG in the blood samples of 45 patients. The disease was moderate and mild in 25.9 % and 74.1%, respectively. The clinical symptoms were absent or were less noticeable in 20% of the patients. The patients had fever (82.9%), weakness (75%), anosmia (53.9%), dry cough (35.5%), and dyspnea (5.3%). Lung CT changes were recorded in 28 out of 38 patients (CT3 in 1). No therapy for coronavirus infection was performed in 24.7% of the patients. 6.25% of patients received antiviral therapy; 15.6% took hydroxychloroquine in combination with antibacterial therapy (ABT); 75% had ABT; 21.9 and 4.9% used anticoagulants and corticosteroids, respectively.
Conclusion. Coronavirus infection was mild in 3/4 of the patients with HIV infection, asymptomatic or subtle in 20%, which was probably due to the regular follow-up of this patient category, to effective ART in 89.4%, to the young age of patients, and to the absence of concomitant diseases in most patients.
Literature
1. Tesoriero J.M., Swain С.А., Pierce J.L., Zamboni L., Wu M., Holtgrave D.R. et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021; 4(2): e2037069. doi:10.1001/jamanetworkopen.2020.37069 2. Bhaskaran K., Rentsch C.T., MacKenna B., Schultze A., Mehrkar A., Bates C.J. et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the Open SAFELY platform. Lancet 2021; 8(1): E24–E32. DOI:10.1016/S2352-3018(20)30305-2 3. Hoffmann C., Casado J.L., Härter G., Vizcarra P., Moreno A., Cattaneo D. et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Medicine 2021; 22: 372–8. doi.org/10.1111/hiv. 13037 4. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России. Версия 11 (07.05.2021). https://static-0.minzdrav. gov.ru/system/attachments/attaches/000/055/736/original/BMP-11.pdf [Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Temporary guidelines of the Ministry of Health of Russia. Version 11 (07.05.2021). (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/736/ original/BMP-11.pdf 5. Guidance for COVID-19 and Persons with HIV (last updated February 26, 2021): National Institutes of Health, Office of AIDS Research. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/HIV_COVID_19_GL_2021.pdf 6. Руженцова Т.А., Чухляев П.В., Хавкина Д.А., Гарбузов А.А., Плоскирева, А.А., Осешнюк Р.А. и др. Эффективность и безопасность применения фавипиравира в комплексной терапии COVID-19 легкого и среднетяжелого течения. Инфекционные болезни: новости, мнения, обучение 2020; 9(4): 26–38. DOI: https://doi.org/10.33029/2305- 3496-2020-9-4-26-38 Ruzhentsova T.A., Chukhlyaev P.V., Khavkina D.A., Garbuzov A.A., Ploskireva A.A., Oseshnyuk R.A. et al. [Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19]. Infectious diseases: news, opinions, training 2020; 9(4): 26–38. (In Russ.). DOI: https://doi. org/10.33029/2305- 3496-2020-9-4-26-38 7. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10(4, приложение). 92 с. [Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravcova E.V., Deulina M.O. et al. Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection. Epidemiology and infectious diseases. Current items 2020; 10(4, appendix). 92 p. 8. Кравченко А.В., Ладная Н.Н., Козырина Н.В., Покровский В.В., Юрин О.Г., Соколова Е.В., Дементьева Л.А. Причины летальных исходов среди лиц, инфицированных ВИЧ, в Российской Федерации в 2008–2018 гг. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10(3): 63–9. DOI: https://dx.doi.org/10.18565/epidem. 2020.10.3.63–9 Kravchenko A.V., Ladnaia N.N., Kozyrina N.V., Pokrovsky V.V., Yurin O.G., Sokolova E.V., Dementyeva L.A. [Causes of deaths among HIV-infected persons in the Russian Federation in 2008–2018]. Epidemiology and infectious diseases. Current items 2020; 10(3): 63–9. DOI: https://dx.doi. org/10.18565/epidem. 2020.10.3.63–9
About the Autors
Рrofessor Alexey V. Kravchenko, МD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; alexey-kravtchenko@yandex.ru; http://orcid.org/0000-0001-7857-3763
Ulyana A. Kuimova, Cand. Med. Sci., Researcher, Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; ulyanakuimova@gmail.com; https://orcid.org/0000-0002-1101-151X
Veronika G. Kanestri, MD, Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; kanestri@yandex.ru; http://orcid.org/0000-0002-2234-7094
Marina D. Goliusova, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; mad2501@yandex.ru; https://orcid.org/0000-0002-5325-6857
Ekaterina I. Kulabukhova, Infectiologist, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Head, Laboratory of the Department of Infectious Diseases with Courses in Epidemiology and Phthisiology of the Medical Institute, Peoples’ Friendship University of Russia, Moscow, Russia; ekulabukhova@mail.ru; https://orcid.org/0000-0003-3645-7275
Similar Articles
